Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Feb 16. pii: S2152-2650(14)00045-7. doi: 10.1016/j.clml.2014.02.003. [Epub ahead of print]

PMID:
24650974
[PubMed - as supplied by publisher]
2.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
[PubMed - indexed for MEDLINE]
3.

Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.

Lee BH, Shin SH, Min CK, Yhim HY, Kwak JY, Kim JA.

Int J Hematol. 2013 May;97(5):634-9. doi: 10.1007/s12185-013-1311-2. Epub 2013 Apr 20.

PMID:
23605366
[PubMed - indexed for MEDLINE]
4.

Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.

Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K.

Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23.

PMID:
23877150
[PubMed - in process]
5.
6.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
[PubMed - indexed for MEDLINE]
Free Article
7.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

PMID:
11704785
[PubMed - indexed for MEDLINE]
Free Article
8.

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.

Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ.

Transplantation. 2010 Oct 27;90(8):905-11. doi: 10.1097/TP.0b013e3181f10edb.

PMID:
20733534
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
[PubMed - indexed for MEDLINE]
10.

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.

Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.

Bone Marrow Transplant. 2000 Aug;26(4):383-8.

PMID:
10982284
[PubMed - indexed for MEDLINE]
Free Article
11.

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.

Blanes M, González JD, Lahuerta JJ, Ribas P, Lorenzo I, Boluda B, Sanz MA, de la Rubia J.

Leuk Lymphoma. 2014 Jul 17:1-5. [Epub ahead of print]

PMID:
24828869
[PubMed - as supplied by publisher]
12.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

PMID:
19733251
[PubMed - indexed for MEDLINE]
13.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

PMID:
9573002
[PubMed - indexed for MEDLINE]
Free Article
14.

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.

Haematologica. 2006 Dec;91(12):1635-43.

PMID:
17145600
[PubMed - indexed for MEDLINE]
Free Article
15.

AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.

van Gameren II, Hazenberg BP, Jager PL, Smit JW, Vellenga E.

Amyloid. 2002 Sep;9(3):165-74.

PMID:
12408679
[PubMed - indexed for MEDLINE]
16.

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA.

Blood. 2012 Feb 2;119(5):1117-22. doi: 10.1182/blood-2011-07-370031. Epub 2011 Dec 6.

PMID:
22147893
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.

Lee SR, Kim SJ, Park Y, Sung HJ, Choi CW, Kim BS.

Korean J Hematol. 2010 Sep;45(3):183-7. doi: 10.5045/kjh.2010.45.3.183. Epub 2010 Sep 30.

PMID:
21120207
[PubMed]
Free PMC Article
18.

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M; Intergroupe Francophone du Myélome (IFM).

Blood. 2010 Jan 7;115(1):32-7. doi: 10.1182/blood-2009-06-229658. Epub 2009 Nov 2.

PMID:
19884643
[PubMed - indexed for MEDLINE]
Free Article
19.

[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].

Li J, Liu JR, Huang BH, Chen M, Zheng D, Xu DR, Zou WY.

Zhonghua Nei Ke Za Zhi. 2012 Apr;51(4):279-83. Chinese.

PMID:
22781947
[PubMed - indexed for MEDLINE]
20.

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.

Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA.

Bone Marrow Transplant. 2005 Oct;36(7):591-6.

PMID:
16062177
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk